📰 Ciences News
Page 150 - Ciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ciences. Real-time updates on events, politics, business and more.
July 7, 2022
TORONTO, July 07, 2022, the omnichannel learning and enablement platform for life sciences, today announced the closing of a US$18 million equity financing. The investment was led by Questa Capital, a
July 7, 2022
This is Urovant's second year in a row to earn this recognition by Orange County Business Journal Urovant has also received a 2022 global Great Place to Work certification. The culmination
July 6, 2022
VERNON, BC, July 6, 2022 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU7) ("Doseology" or the "Company"), a life sciences company focused on mental health and wellness
July 6, 2022
VERNON, BC, July 6, 2022 /CNW/ -- Doseology Sciences Inc. , a life sciences company focused on mental health and wellness, is pleased to announce the approval of its application for an... | July 6, 2022
July 6, 2022
Agreement with Aurora Flight Sciences to Deliver Two Vehicles, Each Designed to Fly Up To 200 Launches Per Year First New Mothership Expected to Enter Service in 2025 Outsourced Manufacturing... | July 6, 2022
July 6, 2022
In a way, author Eliot Schrefer writes in the introduction to his new book, he wrote “Queer Ducks (And Other Animals)” for his 11-year-old self. That’s how old he was
July 6, 2022
WASHINGTON (dpa-AFX) - Usana Health Sciences Inc. (USNA) Wednesday lowered its outlook for the full year 2022. Looking forward to the full year 2022, the company now expects earnings of $3.85 to
July 5, 2022
🔥 À propos de la TVA de lUnion européenne: Les marchandises achetées auprès de Banggood et livrées à la destination située dans lUnion européenne (UE), la TVA et les...<br>
July 5, 2022
VINIA® sales orders reached a record high of USD 947k representing 99% growth compared to Q2 2021 and 24% growth compared to Q1 2022BioHarvest reiterates guidance for year-on-year sales orders growth
July 5, 2022
Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the Europe Economic Area, UK, and Switzerland. Urovant Sciences